Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979688 | 0.86 | STS (0.60) | STSMAPK1KMT2AHTT | |
| SCHEMBL13938176 | 0.83 | STS (0.56) | STSMAPK1KMT2AALDH1A1HTT | |
| SCHEMBL1980404 | 0.81 | HSD17B10 (0.53) | STSMAPK1KMT2AFKBP1AF2 | |
| SCHEMBL1979169 | 0.81 | FKBP1A (0.55) | KMT2AFKBP1AF2PRSS1MEN1 | |
| SCHEMBL1979225 | 0.81 | USP30 (0.50) | STSMAPK1KMT2AALDH1A1MAPT | |
| SCHEMBL13938199 | 0.78 | KDM4E (0.50) | STSMAPK1KMT2AALDH1A1MAPT | |
| SCHEMBL1979768 | 0.78 | FKBP1A (0.52) | KMT2AFKBP1AF2PRSS1MEN1 | |
| SCHEMBL1986802 | 0.77 | FKBP1A (0.48) | KMT2AFKBP1AF2PRSS1MEN1 | |
| SCHEMBL14347227 | 0.77 | KMT2A (0.47) | MAPK1KMT2AALDH1A1MEN1 | |
| SCHEMBL13938153 | 0.77 | POLB (0.45) | STSMAPK1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326833-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | H LEE MOFFITT CANCER CT & RES (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7476680-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7135483-B2 | Substituted heterocyclic compounds for treating multidrug resistance | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20060223853-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| EP-1326833-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020099215-A1 | Substituted heterocyclic compounds for treating multidrug resistance | THE PROCTER GAMBLE CO. | 2002-07-25 | — | — | US | disclosed |
| WO-2002032869-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| US-6376514-B1 | PIPERIDINE-DERIVED COMPOUNDS CONTAINING A QUINOLYL GROUP THAT INHIBITS P-GLYCOPROTEIN TRANSPORT PROTEIN ACTIVITY; FOR TREATING CANCER AND OTHER DISEASES | THE PROCTER & GAMBLE CO. | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223853-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | ABCC1, ABCB1, ABCB11 | STS 347/4885MAPK1 3186/4885KMT2A 3027/4885 |
| US-20020099215-A1 | Substituted heterocyclic compounds for treating multidrug resistance | ABCC1, ABCB1, ABCB11 | STS 568/4885MAPK1 3832/4885KMT2A 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.